Yuri Stasiv
Overview
Explore the profile of Yuri Stasiv including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
855
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tangri N, Mathur V, Bushinsky D, Klaerner G, Li E, Parsell D, et al.
J Am Soc Nephrol
. 2024 Jan;
35(3):311-320.
PMID: 38261535
Significance Statement: Metabolic acidosis is a common complication of CKD and is associated with more rapid decline of kidney function, but well-powered controlled randomized trials testing the effect of treating...
2.
Mathur V, Bushinsky D, Inker L, Klaerner G, Li E, Parsell D, et al.
Nephrol Dial Transplant
. 2022 Nov;
38(6):1448-1458.
PMID: 36331426
Background: Whether treating metabolic acidosis slows progression of chronic kidney disease (CKD) has not been established. Veverimer is a novel hydrochloric acid binder that removes acid from the gastrointestinal tract...
3.
Parsell D, Shao J, Guttendorf R, Mathur V, Li E, Wu Y, et al.
Drug Metab Dispos
. 2021 May;
49(7):490-500.
PMID: 34031138
Veverimer is a polymer being developed as a potential treatment of metabolic acidosis in patients with chronic kidney disease. Veverimer selectively binds and removes hydrochloric acid from the gastrointestinal tract,...
4.
Wesson D, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, et al.
Lancet
. 2019 Jun;
394(10196):396-406.
PMID: 31248662
Background: Metabolic acidosis, a complication of chronic kidney disease, causes protein catabolism and bone demineralisation and is associated with adverse kidney outcomes and mortality. Veverimer, a non-absorbed, counterion-free, polymeric drug...
5.
Wesson D, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, et al.
Lancet
. 2019 Mar;
393(10179):1417-1427.
PMID: 30857647
Background: Patients with advanced chronic kidney disease lose the capacity to fully excrete endogenous acid, resulting in chronic metabolic acidosis that increases the risk of disease progression and causes muscle...
6.
Bushinsky D, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, et al.
Clin J Am Soc Nephrol
. 2017 Nov;
13(1):26-35.
PMID: 29102959
Background And Objectives: Metabolic acidosis is common in patients with CKD and has significant adverse effects on kidney, muscle, and bone. We tested the efficacy and safety of TRC101, a...
7.
Weir M, Bakris G, Gross C, Mayo M, Garza D, Stasiv Y, et al.
Kidney Int
. 2016 Jun;
90(3):696-704.
PMID: 27350174
Elevated serum aldosterone can be vasculotoxic and facilitate cardiorenal damage. Renin-angiotensin system inhibitors reduce serum aldosterone levels and/or block its effects but can cause hyperkalemia. Patiromer, a nonabsorbed potassium binder,...
8.
Pitt B, Bakris G, Bushinsky D, Garza D, Mayo M, Stasiv Y, et al.
Eur J Heart Fail
. 2015 Oct;
17(10):1057-65.
PMID: 26459796
Aims: We evaluated the effects of patiromer, a potassium (K(+))-binding polymer, in a pre-specified analysis of hyperkalaemic patients with heart failure (HF) in the OPAL-HK trial. Methods And Results: Chronic...
9.
Bushinsky D, Williams G, Pitt B, Weir M, Freeman M, Garza D, et al.
Kidney Int
. 2015 Sep;
88(6):1427-1433.
PMID: 26376130
Patients with chronic kidney disease (CKD) have a high risk of hyperkalemia, which increases mortality and can lead to renin-angiotensin-aldosterone system inhibitor (RAASi) dose reduction or discontinuation. Patiromer, a nonabsorbed...
10.
Bakris G, Pitt B, Weir M, Freeman M, Mayo M, Garza D, et al.
JAMA
. 2015 Jul;
314(2):151-61.
PMID: 26172895
Importance: Hyperkalemia is a potentially life-threatening condition predominantly seen in patients treated with renin-angiotensin-aldosterone system (RAAS) inhibitors with stage 3 or greater chronic kidney disease (CKD) who may also have...